Allist(SH:688578)2023-10-25 16:00Financial Performance - The company's revenue for Q3 2023 reached ¥599,127,050.54, representing a year-over-year increase of 175.67%[4] - Net profit attributable to shareholders for Q3 2023 was ¥202,012,904.91, a significant increase of 643.57% compared to the same period last year[4] - The net profit excluding non-recurring gains and losses for Q3 2023 was ¥196,178,109.98, reflecting a remarkable growth of 1,226.74% year-over-year[4] - The basic earnings per share for Q3 2023 was ¥0.45, up 643.57% year-over-year[4] - Total operating revenue for the first three quarters of 2023 reached ¥1,347,801,762.83, a significant increase from ¥517,717,492.02 in the same period of 2022, representing a growth of approximately 160%[16] - Net profit for the third quarter of 2023 was ¥410,427,066.86, compared to ¥53,932,347.03 in the same quarter of 2022, indicating a substantial increase of about 661%[17] - Basic and diluted earnings per share for the third quarter of 2023 were both ¥0.91, up from ¥0.12 in the same quarter of 2022, reflecting a growth of 658%[18] - Total comprehensive income for the third quarter of 2023 was ¥412,056,257.48, compared to ¥58,289,725.34 in the same quarter of 2022, indicating an increase of approximately 608%[17] Assets and Liabilities - The total assets at the end of Q3 2023 amounted to ¥3,974,952,121.41, which is a 15.48% increase from the end of the previous year[5] - As of September 30, 2023, the company's total assets amounted to RMB 3.975 billion, up from RMB 3.442 billion at the end of 2022[14] - Total liabilities and equity as of the end of the third quarter of 2023 were ¥3,974,952,121.41, compared to ¥3,442,172,227.84 in the same period of 2022, reflecting a growth of about 15.5%[17] Cash Flow - The company reported a net cash flow from operating activities of ¥461,873,407.41 for the year-to-date period, reflecting a 1,262.82% increase year-over-year[4] - Cash flow from operating activities for the first three quarters of 2023 was ¥461,873,407.41, a significant increase from ¥33,891,027.22 in the same period of 2022[19] - The net cash flow from investing activities for Q3 2023 was $208.71 million, compared to $344.52 million in Q3 2022, indicating a decrease of approximately 39.4%[20] - The net cash flow from financing activities was -$2.19 million, an improvement from -$4.79 million in the same quarter last year, reflecting a reduction in cash outflow by about 54.3%[20] - The net increase in cash and cash equivalents for Q3 2023 was $674.11 million, significantly higher than $389.14 million in Q3 2022, representing an increase of about 73.3%[20] - The ending balance of cash and cash equivalents was $988.98 million, slightly down from $1.00 billion at the end of Q3 2022[20] Research and Development - Research and development expenses for Q3 2023 totaled ¥78,181,189.54, an increase of 61.67% compared to the same period last year[4] - Research and development expenses for the first three quarters of 2023 totaled ¥191,351,163.78, compared to ¥137,289,093.00 in the same period of 2022, representing an increase of about 39.4%[16] - The proportion of R&D expenses to revenue decreased to 13.05%, down 9.2 percentage points from the previous year[4] - The company is conducting a Phase III clinical trial for the treatment of NSCLC with the drug Furmetinib, which has shown promising preliminary efficacy and safety results[12] - The company has been granted approval for multiple clinical studies, including a trial comparing Furmetinib with platinum-based chemotherapy for specific NSCLC mutations[12] Strategic Outlook - The company anticipates continued growth in sales volume due to the inclusion of its core product in the national medical insurance directory, contributing to revenue expansion[7] - The company aims to continue its strategic development and commercialize its products to achieve excellent operational performance for its investors[12] - The company is focused on enhancing corporate governance and improving overall management quality to strengthen its competitive advantage in core business areas[12] Inventory and Receivables - The company reported a significant increase in accounts receivable, rising to RMB 216.01 million from RMB 150.85 million year-over-year[14] - The company's inventory increased to RMB 60.19 million from RMB 32.07 million year-over-year, reflecting growth in product availability[14]